AVITA Medical Raises 2026 Guidance, Targets Q4 Breakeven

What happened

AVITA Medical delivered second-quarter revenue of $21.7 million, representing 18% year-over-year growth and 13% sequential growth. U.S. RECELL revenue reached $18.5 million, up approximately 13% sequentially, supported by physician utilization following reimbursement stabilization and adoption of RECELL GO mini for smaller wounds. International RECELL revenue climbed roughly 26% sequentially. Newer products also contributed: Cohealyx generated $1.7 million (up approximately 16% sequentially), while PermeaDerm brought in $600,000. Gross margin improved to 81.9%, and operating loss narrowed to $6.9 million from $11.1 million a year earlier. Net cash use improved to approximately $3.2 million during the quarter, with the company ending the period holding about $11.1 million in cash equivalents and marketable securities.

Why it matters

The quarter marked meaningful progress on multiple fronts for AVITA. Revenue acceleration, margin expansion, and narrowing losses signal improving operational leverage. More significantly, management raised full-year revenue guidance to $86–$89 million (implying 20–24% growth over 2025) and introduced new guidance targeting cash-flow breakeven by Q4 2026. This shift from cash consumption to self-sustainability is a key milestone for investors monitoring the company's path to profitability. The sequential uptick in RECELL GO mini adoption and Cohealyx hospital reviews suggests the product portfolio is gaining traction beyond the core RECELL platform, potentially broadening the addressable market and reducing reliance on a single product line.

Bigger picture

AVITA operates in the therapeutic acute wound care market, where regenerative technologies and advanced wound matrices compete for hospital adoption. The company's RECELL platform harnesses a patient's own skin to create Spray-On Skin for burn and trauma wounds, offering a differentiated approach versus traditional grafting or dermal substitutes. Cohealyx and PermeaDerm expand AVITA's portfolio into collagen-based and biosynthetic matrices, positioning the company to capture a broader range of wound types. Hospital value analysis committee reviews-approximately 55 active, with 10–15 completed quarterly-reflect the slow but deliberate adoption cycle typical of advanced wound products. The upcoming publication of six-month follow-up data from the Cohealyx-I clinical study, showing faster time to skin graft readiness versus leading dermal matrices, could reinforce clinical differentiation and support further hospital approvals. Internationally, RECELL holds regulatory approvals in Europe, Australia, New Zealand, and Japan, suggesting runway for geographic expansion as the company approaches domestic profitability.

What to watch

Investors should monitor quarterly progress toward the Q4 cash-flow breakeven target, as any delays or margin pressures could raise questions about sustainability. Track the pace of Cohealyx hospital approvals and whether the 10–15 quarterly cadence accelerates following publication of the Cohealyx-I six-month data. Sequential growth in PermeaDerm revenue and international RECELL sales will signal whether the portfolio diversification strategy is succeeding. Additionally, watch for updates on RECELL GO mini utilization trends and physician reimbursement stability, both of which underpin U.S. volume growth. Any commentary on operating expense discipline will be important, given the company's commitment to reaching breakeven without significant cost increases.